(Q44704443)

5 December 2017

0 references

Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model (English)

1 reference

5 December 2017

Marchetti A

1

1 reference

5 December 2017

Piech CT

2

1 reference

5 December 2017

McGhan WF

3

1 reference

5 December 2017

Neugut AI

4

1 reference

5 December 2017

Smith BT

5

1 reference

5 December 2017

publication date

1 July 1996

1 reference

5 December 2017

published in

Clinical Therapeutics

1 reference

5 December 2017

volume

18

1 reference

5 December 2017

issue

4

1 reference

5 December 2017

page(s)

757-77; discussion 702

1 reference

Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Onychomycosis, tinea pedis and tinea manuum caused by non-dermatophytic filamentous fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Mycology of nail disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Fungal infection as a cause of skin disease in the Eastern Province of Saudi Arabia: prevailing fungi and pattern of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Clinical and mycological diagnostic aspects of onychomycoses and dermatomycoses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

1 reference

7 January 2021

Quality of life of persons with onychomycosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

New approaches to the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Fungal nail disease: a guide to good practice (report of a Working Group of the British Society for Medical Mycology)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Clinical pearl: systemic antifungal drugs and drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Terbinafine: An oral and topical antifungal agent

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. The Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Development of outcome-based practice guidelines: a method for structuring problems and synthesizing evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Onychomycosis: successful treatment with once-weekly fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Recalcitrant onychomycosis of the toenails successfully treated with fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Meta-analysis for combining Bayesian probabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Onychomycosis Treated with Itraconazole or Griseofulvin Alone with and without a Topical Antimycotic or Keratolytic Agent

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Open randomized comparison of itraconazole versus terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Treatment of onychomycosis with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Further Experiences with Ketoconazole in the Treatment of Onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Seventh Lamisil German Onychomycosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Mycological and clinical evaluation of griseofulvin for chronic onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

An effective oral antifungal for chronic infections in the aged.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

The Activity of Ketoconazole in the Treatment of Onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Short term treatment of dermatophyte onychomycosis with terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Treatment of chronic dermatophytosis and chronic oral candidosis with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

An evaluation of itraconazole in the management of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Ketoconazole in the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Comparative effects of griseofulvin on onychomycosis and on psoriasis unguium

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Efficacy and safety of itraconazole in the long-term treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Onychomycosis treated with ultrafine griseofulvin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Oral Therapy with Ketoconazole for Dermatophyte Infections Unresponsive to Griseofulvin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Ketoconazole in griseofulvin-resistant dermatophytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Terbinafine in onychomycosis--a mini study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

An Evaluation of Two Years of Clinical Experience with Ketoconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

A randomized treatment duration-finding study of terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

A method for the determination of drug effectiveness in onychomycosis. Trials with ketoconazole and griseofulvin ultramicrosize

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Rank-order stability analysis (ROSA): testing pharmacoeconomic data

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980225-6

7 January 2021

10.1016/S0149-2918(96)80225-6

Identifiers

DOI

1 reference

5 December 2017

1 reference